Ovarian Cancer Clinical Trial
Official title:
Diaphragmatic Resection And Gynecological Ovarian Neoplasm
Prospective randomized phase IV study aimed to value the impact of diaphragmatic surgery and
the useful of intra-operatory thoracic drain in advanced ovarian cancer.
Considering the fact that the diaphragmatic surgery could contribute with the incidence of
post-operatory morbidity. The study is aimed to value the role of thoracic drain in
post-operative outcomes as hospital stay, time to chemotherapy, drugs use and eventual
interventions.
Ovarian cancer represents the leading cause of death from gynecologic malignancies. The
majority of patients present with advanced-stage disease (III/IV) often involving the upper
abdomen. Spread by either direct extension or via peritoneal implantation can result in
metastases to the diaphragm, as seen in up to 40% of patients with advanced disease.
Standard treatment of advanced-stage disease includes primary cytoreductive surgery followed
by combination platinum-taxane chemotherapy. Optimal cytoreduction to ≤1 cm disease has
repeatedly been shown to be associated with improved survival.
Diaphragm involvement was considered one of the most frequent obstacles to achieving optimal
cytoreduction. The right diaphragm is more frequently and extensively involved than the left
diaphragm; however, bilateral involvement is not uncommon. Various studies have advocated and
reported the feasibility of diaphragmatic surgery in achieving optimal cytoreduction.
Sometimes, depending on extent of the disease, the diaphragm involvement could be massive and
often the resection of the muscle with access to pleural cavity is necessary. Allegedly,
entering the pleural cavity increases the morbidity of the procedure.
Extensive upper abdominal surgery involving diaphragmatic peritonectomy/resection and liver
mobilization may both contribute to the development of symptomatic pleural effusions.
The aim of the study is to value the impact of diaphragmatic surgery in post-operative
complications using a specific score (DRS). The other aim is to asses a correct management of
intra-operatory thoracic drain position after diaphragmatic surgery. All parameter that could
influence the post-operative outcomes as (EBL,BMI, OT, SCS) are recorded.
The study was approved by Ethical Committee of Fondazione Policlinico Gemelli Hospital (prot
n. 9078/18).
The study is a superiority randomized clinical trial to investigate the role of
intra-operative chest tube in the large (> 5 cm) diaphragmatic peritonectomy/resection in the
ovarian cancer debulking. Calculation of sample size for the analysis of the primary
end-point (major pleural effusion) was based on literature results reporting a rate of
moderate/severe early peri-operative pleural effusion between 54% and 23% when a large (> 5
cm) diaphragmatic resection is performed. A sample size of 88 patients was required in order
to provide 80% power of detecting a reduction of 60% of moderate/severe pleural effusion in
PDS with large diaphragmatic resection when intra-operative chest tube was inserted (overall
rate 22%) (two-tailed α =0.05, drop-out 5%).
Sample size is composed by 44 Patients affected by advanced stage ovarian cancer, meeting
inclusion criteria, undergo diaphragmatic surgery followed by intra-operatory thoracic drain
position and 44 patients with same characteristics undergo to diaphragmatic surgery without
intra-operatory thoracic drain position. Both groups are compared in terms of incidence of
post-operative complications (especially pleural effusion, pneumothorax, respiratory
disease). Secondary endpoints are the evaluation of surgical outcomes and clinical outcomes
in terms hospital stay, procedures and radiologic examinations required. All patients are
adequately informed and inserted in the study only after having read and signed an informed
consent. Diagnostic, clinical and surgical data of each patient are prospectively recorded.
Surgical procedures consist of surgical standard cytoreduction, performed for all cases of
advanced stage ovarian cancer disease. The procedures performed depending on disease spread.
The diaphragmatic procedures, depending on the disease infiltration can consists of
superficial peritonectomy, deep peritonectomy (until muscular layer) or diaphragmatic
resection. Considering the randomization, if required, a thoracic drain tube 24 Fr. is
positioned. A post-operative chest X-Ray is performed on all cases.
At the end of the procedure, a schedule is compiled with intraoperative data.
Post-operative examinations are follows:
- Chest X-Ray (2 h post-op)
- Chest X-Ray (day 1)
- Chest X-Ray (if required, depending of clinical indications)
- Thoracic US scan evaluation before discharge
- Thoracic US scan evaluation 10 days after discharge
- Radiological examinations (if required, depending of clinical indications)
All clinical and histologic data will be recorded prospectively using an electronic database.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |